Key Takeaways:
Several law firms have opened investigations into GeneDx Holdings Corp. following a significant drop in the company's stock price, examining whether the genomics company may have violated federal securities laws. The probes were announced by firms including Kirby McInerney LLP, Block & Leviton, and Barrack, Rodos & Bacine on behalf of investors.
"The investigation is ongoing to determine whether claims may be brought under federal securities laws," Kirby McInerney LLP said in a statement. The firm encouraged investors who purchased GeneDx securities to contact them to discuss their rights.
The investigations follow GeneDx's first-quarter 2026 financial results, released on May 4, which saw the company report a $57.5 million loss from operations and an earnings per share of -$0.28. GeneDx also lowered its full-year 2026 revenue guidance by about $65 million, citing lower reimbursement rates and underperformance in its non-core business lines.
The disappointing results triggered a massive sell-off in GeneDx shares, which plummeted by approximately 50% from $67.93 on May 4 to $34.51 on May 5. The company also disclosed a $31.3 million write-down related to its Fabric Genomics unit, attributing it to a "downward revision of forecasted cash flows."
The sharp decline in share price and subsequent investigation could lead to a class-action lawsuit, adding legal and financial pressure on GeneDx. Investors will be closely watching for the outcome of these investigations and any potential legal action.
This article is for informational purposes only and does not constitute investment advice.
